


CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James Epperson
Type or print name

James Epperson
Signature

March 31, 2004
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

E. SCOTT PRIESTLEY

APPLICATION NO: 10/759,725

FILED: JANUARY 15, 2004

FOR: PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/039,317 filed October 23, 2001, and copies are available therein. However, applicant is willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
203-677-6974



James Epperson
Agent for Applicants
Reg. No. 52,867


Date: March 31/2004

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7148A DIV1
APPLICATION NO.
10/759,725
APPLICANT
E. Scott Priestley
FILING DATE
January 15, 2004

Group -

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AI	WO 98/17679	4/30/98	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 98/22496	5/28/98	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 99/07734	2/18/99	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 99/07733	2/18/99	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 99/50230	10/7/99	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 00/09543	2/24/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 00/09558	2/24/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 98/46630	10/22/98	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 97/43310	11/20/97	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	C. Steinkuhler, et al, "Product Inhibition of the Hepatitis C Virus NS3 Protease," BIOCHEMISTRY, 37, pp. 8899-8905, 1998
	AS	P. Ingallinella, et al, "Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products," BIOCHEMISTRY, 37, pp. 8906-8914, 1998
	AT	E. Pizzi, et al, "Molecular Model of the Specificity Pocket of the Hepatitis C Virus Protease: Implications for Substrate Recognition," PROC. NATL. ACAD. SCI. USA, 91, pp. 888-892, 1994

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7148A DIV1
APPLICATION NO.
10/759,725
APPLICANT
E. Scott Priestley
FILING DATE
January 15, 2004

Group -



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AU	A. Urbani, et al, "Substrate Specificity of the Hepatitis C Virus Serine Protease NS3," THE JOURNAL OF BIOLOGICAL CHEMISTRY, 272(14), pp. 9204-9209, 1997
AV	R. B. Perni, "NS3•4A Protease as a Target for Interfering with Hepatitis C Virus Replication," DRUG NEWS PERSPECT, 13(2), pp. 69-77, 2000
AW	
AX	
AY	
AZ	
BA	
BB	
BC	
BD	
BE	
BF	
BG	
BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.